Fundraising Fox

Xios Therapeutics

Waltham, US · Founded 2015 · Delaware corporation

Elpis Biopharmaceuticals is a clinical-stage biopharma company developing bispecific armored CAR-T cell therapies for solid tumors, addressing tumor heterogeneity and the immunosuppressive tumor microenvironment. Its pipeline includes EPC-003 for glioblastoma and EPC-002 for a range of solid tumors, built on proprietary armor, bispecific antibody, cell manufacturing, and mRNA display discovery platforms.

BiotechHealthtech

Founders & leadership

Xios Therapeutics was founded in 2015 by Yan Chen.

YCYan Chen
Yan CheninFounderDr. Yan Chen holds an M.D. and Ph.D., with 25 years of experience in biologics and cell therapy development, including leadership roles advancing technology platforms and clinical programs in biotherapeutics.
DE
Diala EzzeddineNamed on SEC filing

Board

JB
Jeff BirdBoard director
RW
Rick WagnerBoard director

Reported raises · per SEC filings

Form D private placements

$7M disclosed across 2 rounds · 2015–2018

▶$1MraisedJul 2018 · 21 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Rick WagnerDirector
  • Jeff BirdDirector
  • Diala EzzeddineExecutive Officer, Director
Offering amount
$1.5M
Amount sold
$1M
First sale
Jun 2018
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6MraisedDec 2015 · 27 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Rick WagnerDirector
  • Diala EzzeddineExecutive Officer, Director
  • Jeff BirdDirector
Offering amount
$6M
Amount sold
$6M
First sale
Dec 2015
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap
Epi Biologics14 shared keywordsEpibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
Ellipses Pharma11 shared keywordsEllipses Pharma develops cancer treatments targeting unmet clinical needs across various cancer types and molecular mechanisms.
IQVIA10 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Exelixis9 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.

Companies competing with Xios Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Xios Therapeutics do?
Elpis Biopharmaceuticals is a clinical-stage biopharma company developing bispecific armored CAR-T cell therapies for solid tumors, addressing tumor heterogeneity and the immunosuppressive tumor microenvironment. Its pipeline includes EPC-003 for glioblastoma and EPC-002 for a range of solid tumors, built on proprietary armor, bispecific antibody, cell manufacturing, and mRNA display discovery platforms.
Who founded Xios Therapeutics?
Xios Therapeutics was founded by Yan Chen in 2015.
How much funding has Xios Therapeutics raised?
Xios Therapeutics has disclosed $7M raised across 2 rounds.
Where is Xios Therapeutics headquartered?
Xios Therapeutics is headquartered in Waltham, US.